BlueCross BlueShield MI and Cambia Health Solutions Expand TMS Access for Depressed Adolescents
Updated criteria post-FDA clearance for NeuroStar TMS benefit youth mental healthMALVERN, Pa., July 10, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc....
Neuroscience
Scanning Electrochemical Microscopy (SECM) Market size is set to grow by USD 55.8 million from 2024-2028, Miniaturization of electronic devices boost the market, Technavio
NEW YORK, July 9, 2024 /PRNewswire/ -- Scanning electrochemical microscopy (SECM) is used for imaging and analyzing chemical processes at...
Cresilon’s Revolutionary Hemostatic Gel Technology Shows Promising Results for Treatment of Penetrating Traumatic Brain Injury in Study Performed with Walter Reed Army Institute of Research
Findings from preclinical study demonstrate potential for a field and prehospital treatment following a penetrating TBI NEW YORK, July 9,...
Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team
MALVERN, Pa., July 09, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”),...
AEON Biopharma Announces Strategic Reprioritization to Pursue a Biosimilar Pathway for ABP-450
– Plan to move ahead with a head-to-head comparison to BOTOX® in a cervical dystonia Phase 3 study via the...
uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease
~ Achieved statistically significant, dose-dependent, and durable evidence of potential therapeutic benefit; Patients receiving high-dose AMT-130 showed 80% slowing of...
Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
Corundum Neuroscience Awards Research Grant to Explore Machine Learning for Non-Invasive Detection of Dementia-Associated Brain Activity During Sleep
Research Project with Tel Aviv University to Focus on Optimizing Identification of Early-Stage Dementia and Improving Diagnosis and Treatment for...
NeuroStar® Launches Better Me Provider Program Nationwide
The first and only TMS company to establish comprehensive standards for patient care and responsiveness in the mental health industryMALVERN,...
ONWARD® Medical Obtains Debt Financing with up to €52.5 Million Secured Loan from Runway Growth Capital LLC
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Runway...
Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease
Data demonstrates improvement in cognitive function in GBA1 Parkinson’s disease model in addition to reversal of motor function deficitsBETHESDA, Md.,...
INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial
The planned interim analysis confirms the accuracy of the sample size calculations and statistical power for EMACC, the primary endpoint....
STALICLA publishes pioneering phase 1b data on precision treatment for autism spectrum disorder in Biomedicines
Press Release STALICLA’s precision psychiatry study highlights strong EEG-based target engagement of STP1 treatment in defined subgroup of patients with...
Neurophet to present brain stimulation simulation study at OHBM 2024
- Presents a poster identifying tDCS effects for patients with AD and cognitively normal people - Showcases brain imaging treatment planning...
AMSBIO and Bioz Combine Efforts to Empower the Scientific Community With Citation Data
PALO ALTO, CA / ACCESSWIRE / June 26, 2024 / Bioz, Inc., a pioneer in AI-driven research solutions, is delighted...
Linus Health Introduces Person-Centered Approach to Establish Clinically Meaningful Benefits and Personalized Brain Health Care
Scalable, systematic and automated process captures and monitors metrics based on patients' treatment priorities for managing Alzheimer's disease and related dementias...
NXTSTIM EcoAI™ using Novel Artificial Intelligence Machine Learning (AIML) Technology with Transcutaneous Nerve and Electromyographic Stimulation shows outstanding 18-month real-world outcomes data with a Remote Patient Monitoring platform (RPM)
SAN DIEGO, June 25, 2024 /PRNewswire/ -- NXTSTIM will present their 18-month real-world outcomes data using EcoAI™ at the American Society...
Zeto Announces Winners of Clinical Trial Sponsorship Program
SANTA CLARA, Calif., June 25, 2024 /PRNewswire/ -- Zeto, Inc., an award-winning medical technology firm, is proud to announce the...
BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI™ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia
Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose)...
Roche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis
OCREVUS subcutaneous (SC) injection offers a new, 10-minute administration of OCREVUS with comparable efficacy and safety to intravenous infusion (IV)...